Latest Videos |view all videos
S. Vincent Rajkumar, M.D., a hematologist from Mayo Clinic in Rochester, Minnesota, discusses his article appearing in the October 2012 issue of Mayo Clinic Proceedings, where he explains the reasons behind the high cost of cancer treatments in the U.S.
Jacob J. Strand, M.D., a general internist from the Section of Palliative Care Medicine at Mayo Clinic in Rochester, Minnesota, explains the role of palliative care in catastrophic illnesses.
J. Taylor Hays, M.D., associate professor of medicine at Mayo Clinic in Rochester, Minnesota, discusses his article appearing in the March 2011 issue of Mayo Clinic Proceedings.
Dr. Ganapathy A. Prasad, Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic in Rochester, MN, discusses his article appearing in the December 2011 issue of Mayo Clinic Proceedings.
S. Vincent Rajkumar, M.D., reviews his Olmsted County population-based study investigating the detection of high polyclonal free light chain levels as a predictor of mortality outcomes across multiple conditions.
S. Vincent Rajkumar, M.D., in the Department of Hematology at Mayo Clinic, introduces and explains the importance of recognizing monoclonal gammopathies as a major cause of proliferative glomerulonephritis.
Sanjeev Sethi, M.D., Ph.D., a professor of laboratory medicine and pathology at Mayo Clinic, presents findings that define the role of monoclonal proteins in proliferative glomerulonephritis and propose evaluation and new treatment algorithms ...
Noting a 2-fold increase in risk of Barrett's Esophagus, Dr. Cadman Leggett, a fellow in gastroenterology at Mayo Clinic in Rochester, MN, discusses his article appearing in the February 2013 issue of Mayo Clinic Proceedings.
Jerry D. Brewer, M.D., M.S., a dermatologic surgeon from the Department of Dermatology at Mayo Clinic in Rochester, Minnesota, unmasks a previously unknown higher risk of melanoma in immunosuppressed and transplant patients.
Mayo Clinic researchers along with collaborators from Life Technologies are reporting on the application of a new approach for sequencing RNA to study cancer tumors.
An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of people with metastatic colorectal cancer, an international phase III clinical trial found.
Matthew K. Tollefson, M.D., provides patients and clinicians with a novel way to predict which cases of prostate cancer, the most commonly diagnosed malignancy in American men, will be aggressive and which ones can be safely monitored with watchful waiting.